Display options
Cite
Ahlqvist E, Prasad RB, Groop L. Towards improved precision and a new classification of diabetes mellitus. J Endocrinol. 2021;doi: 10.1530/JOE-20-0596.
Ahlqvist, E., Prasad, R. B., & Groop, L. (2021). Towards improved precision and a new classification of diabetes mellitus. The Journal of endocrinology, . https://doi.org/10.1530/JOE-20-0596
Ahlqvist, Emma, et al. "Towards improved precision and a new classification of diabetes mellitus." The Journal of endocrinology vol. (2021). doi: https://doi.org/10.1530/JOE-20-0596
Ahlqvist E, Prasad RB, Groop L. Towards improved precision and a new classification of diabetes mellitus. J Endocrinol. 2021 Nov 01; doi: 10.1530/JOE-20-0596. Epub 2021 Nov 01. PMID: 34783681.
Copy Download .nbib Format: NLM
Share it on

J Endocrinol. 2021 Nov 01; doi: 10.1530/JOE-20-0596. Epub 2021 Nov 01.

Towards improved precision and a new classification of diabetes mellitus.

The Journal of endocrinology

Emma Ahlqvist, Rashmi B Prasad, Leif Groop

Affiliations

  1. E Ahlqvist, Department of Clinical Sciences, Genomics, Diabetes and Endocrinology, Lund University, Malmö, Sweden.
  2. R Prasad, Department of clinical sciences, genomics, diabetes and endocrinology, Lund University, Malmö, Sweden.
  3. L Groop, Deparment of clinical sciences, Genomics, Diabetes and Endocrinology, Lund University, Malmö, Sweden.

PMID: 34783681 DOI: 10.1530/JOE-20-0596

Abstract

Type 2 diabetes (T2D) is one of the fastest increasing diseases worldwide. Although it is defined by a single metabolite, glucose, it is increasingly recognized as a highly heterogeneous disease with varying clinical manifestations. Identification of different subtypes at an early stage of disease when complications might still be prevented could hopefully allow for more personalized medicine. An important step towards precision medicine would be to target the right resources to the right patients, thereby improving patient health and reducing health costs for the society. More well-defined disease populations also offer increased power in experimental, genetic and clinical studies. In a recent study, we used six clinical variables (GAD autoantibodies, age at onset of diabetes, HbA1c, BMI, and simple measures of insulin resistance and insulin secretion (so called HOMA estimates) to cluster adult-onset diabetes patients into five subgroups. These subgroups have been robustly reproduced in several populations worldwide and are associated with different risks of diabetic complications and responses to treatment. Importantly, the group with severe insulin-deficient diabetes (SIDD) had increased risk of retinopathy and neuropathy, whereas the severe insulin-resistant diabetes (SIRD) group has the highest risk for diabetic kidney disease (DKD) and fatty liver. This emphasizes the key role of insulin resistance in the pathogenesis of DKD and fatty liver in T2D. In conclusion, this novel sub-classification, breaking down T2D in clinically meaningful subgroups, provides the prerequisite framework for expanded personalized medicine in diabetes beyond what is already available for monogenic and to some extent type 1 diabetes.

Publication Types